Jounce Therapeutics Inc (JNCE)

NASDAQ

Currency in USD

1.880

0.000(0.00%)

Closed·03/05

Day's Range

1.880

1.930

52 wk Range

1.880

1.930

JNCE Income Statement

Explore the detailed Jounce Therapeutics Inc income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Jounce Therapeutics Inc's growth trends and overall financial health.

Period Ending:

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

Total Revenues

aa.aa

65.2

147.87

62.34

26.91

Total Revenues Growth

aa.aa

-8.99%

+126.79%

-57.84%

-56.84%

+204.75%

Cost Of Revenues

aa.aa

31.17

25.88

36.99

44.71

54.8

Gross Profit

aa.aa

34.03

122

25.35

-17.8

27.2

Gross Profit Growth

aa.aa

-18.31%

+258.47%

-79.22%

-170.22%

+252.8%

Gross Profit Margin %

aa.aa

52.2%

82.5%

40.66%

-66.15%

33.17%

Other Operating Expenses, Total

aa.aa

65.33

69.18

70.46

73.26

79.44

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+7.31%	+5.9%	+1.86%	+3.96%	+8.44%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	33.16	35.45	36.18	38.94	43.78
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	32.17	33.73	34.29	34.31	35.66
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-31.29

52.82

-45.12

-91.06

-52.24

Operating Income Growth

aa.aa

-62.86%

+268.78%

-185.42%

-101.82%

+42.63%

EBIT Margin %

aa.aa

-48%

35.72%

-72.37%

-338.41%

-63.71%

Net Interest Expenses

aa.aa

2.85

2.57

1.34

1.12

2.36

Net Interest Expenses Growth

aa.aa

-28.29%

-9.88%

-48.06%

-16.17%

+110.8%

Interest Expense, Total

aa.aa

Interest And Investment Income

aa.aa

2.85

2.57

1.34

1.12

2.36

Other Non Operating Expenses, Total

aa.aa

EBT, Excl. Unusual Items

aa.aa

-28.44

55.39

-43.78

-89.94

-49.88

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

EBT, Incl. Unusual Items

aa.aa

-27.33

56.87

-43.83

-90.86

-50.78

EBT, Incl. Unusual Items Growth

aa.aa

-66.59%

+308.06%

-177.07%

-107.3%

+44.11%

EBT, Incl. Unusual Items Margin

aa.aa

-41.92%

38.46%

-70.31%

-337.67%

-61.93%

Income Tax Expense

aa.aa

0.05

0.01

0.02

0.14

Net Income to Company

aa.aa

-27.38

56.82

-43.84

-90.87

-50.92

Minority Interest

aa.aa

Net Income

aa.aa

-27.38

56.82

-43.84

-90.87

-50.92

Net Income Growth

aa.aa

-66.51%

+307.54%

-177.16%

-107.27%

+43.97%

Net Income Margin %

aa.aa

-41.99%

38.43%

-70.33%

-337.73%

-62.1%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-27.38

56.82

-43.84

-90.87

-50.92

Basic EPS - Continuing Operations

aa.aa

-0.84

1.72

-1.24

-1.82

-0.99

Basic EPS - Continuing Operations Growth

aa.aa

-46.59%

+304.32%

-172.05%

-47.06%

+45.86%

Diluted EPS - Continuing Operations

aa.aa

-0.84

1.66

-1.24

-1.82

-0.99

Diluted EPS - Continuing Operations Growth

aa.aa

-46.59%

+297.46%

-174.7%

-46.77%

+45.86%

Basic Weighted Average Shares Outstanding

aa.aa

32.57

33.08

35.43

49.93

51.68

Diluted Weighted Average Shares Outstanding

aa.aa

32.57

34.29

35.43

49.93

51.68

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-27.46

56.67

-41.72

-88.23

-50.16

EBITDA Growth

aa.aa

-85.65%

+306.34%

-173.61%

-111.5%

+43.15%

EBITDA Margin %

aa.aa

-42.12%

38.32%

-66.92%

-327.9%

-61.16%

EBIT

aa.aa

-31.29

52.82

-45.12

-91.06

-52.24

* In Millions of USD (except for per share items)

US 30

44,484.10

+25.8

+0.06%

US 500

6,264.00

+0.7

+0.01%

Dow Jones

44,458.30

+217.54

+0.49%

S&P 500

6,263.28

+37.76

+0.61%

Nasdaq

20,611.34

+192.87

+0.95%

S&P 500 VIX

15.94

-0.87

-5.18%

Dollar Index

97.16

-0.010

-0.01%

Market Movers

Name	Last	Chg. %	Vol.
NVDA	162.88	+1.80%	176.45M
TSLA	295.94	-0.63%	73.87M
PLTR	143.13	+2.45%	66.66M
AAPL	211.14	+0.54%	47.85M
AMZN	222.54	+1.45%	37.48M
MSFT	503.51	+1.39%	18.26M
META	732.78	+1.68%	11.31M

Trending Stocks

Name	Last	Chg. %	Vol.
NVDA	162.88	+1.80%	176.45M
TSLA	295.94	-0.63%	73.87M
PLTR	143.13	+2.45%	66.66M
INTC	23.44	-0.64%	67.75M
AAPL	211.14	+0.54%	47.85M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaa	309.78	+47.32%	456.37
Aa A Aa Aaaaaaaaaaa	83.71	+44.51%	120.97
Aaaaa	35.61	+43.11%	50.96
Aaaaa Aaaaaaa	132.94	+42.17%	189.00
Aaaaaa Aaaaaaaaa	109.40	+32.17%	144.59
Aaaa A	85.79	+29.66%	111.24
A Aaaa	196.14	+27.85%	250.76

Name	Last	Upside	Fair Value
Aaaaaaaaaa	309.78	+47.32%	456.37
Aa A Aa Aaaaaaaaaaa	83.71	+44.51%	120.97
Aaaaa	35.61	+43.11%	50.96
Aaaaa Aaaaaaa	132.94	+42.17%	189.00
Aaaaaa Aaaaaaaaa	109.40	+32.17%	144.59
Aaaa A	85.79	+29.66%	111.24
A Aaaa	196.14	+27.85%	250.76

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Name	Last	Chg. %	Vol.
AES	13.26	+19.78%	66.66M
PTC	210.47	+17.65%	3.80M
DHI	138.41	+5.36%	5.63M
ENPH	42.85	+4.67%	10.27M
MSTR	415.41	+4.65%	12.57M
BLDR	133.00	+4.53%	2.68M
PHM	113.77	+4.49%	2.81M

Name	Last	Chg. %	Vol.
FICO	1,591.73	-6.54%	627.54K
HSY	161.95	-4.70%	3.51M
MNST	59.54	-3.33%	9.71M
MO	57.75	-3.01%	22.11M
OMC	72.50	-2.89%	6.48M
GL	117.60	-2.88%	941.92K
BAX	29.81	-2.77%	6.95M

Popular Searches

Please try another search

Jounce Therapeutics Inc (JNCE)

JNCE Income Statement

Trending Stocks